CC-1088 is a thalidomide analogue inhibitor of phosphodiesterase 4 that was being developed up to 2005 by Calgene Corp., for treating of inflammatory diseases and myelodysplastic syndromes.[1] CC-10004 was found to be a preferable.[2]


  1. K. Dredge (May 2005). "CC-1088 Celgene". Current Opinion in Investigatoional Drugs. 6 (5): 513–7. PMID 15912966.
  2. Molostvov G, Morris A, Rose P, Basu S, Muller G (February 2004). "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures". British Journal of Haematology. 124 (3): 366–75. doi:10.1046/j.1365-2141.2003.04777.x. PMID 14717786.

External links

This article is issued from Wikipedia - version of the 5/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.